5-HT1B receptor agonists promote Schwann cell myelination
PLOS One · 27.03.2026 · 21 (3) · e0345946
DOI: 10.1371/journal.pone.0345946 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 27.03.2026. Verfasst von Yuka Kobayashi-Ujiie und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Peripheral Nervous System Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan. Hauptthemen laut MEDLINE: Schwann Cells, Myelin Sheath, Serotonin 5-HT1 Receptor Agonists, Receptor, Serotonin, 5-HT1B. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Dainippon Sumitomo Pharma, Masato Kawano Memorial Public Interest Foundation for Promotion of Pediatrics.
Abstract (Originalsprache)
Congenital demyelinating peripheral neuropathy causes severe sensorimotor defects, affecting patient mobility. To identify therapeutic compounds for peripheral hypomyelinating neuropathy, we performed an unbiased screening of annotated compound library by in vitro myelination culture model using Trembler (Tr-Ncnp) -derived dorsal root ganglia explants. Among the compounds identified in the screening, we confirmed that zolmitriptan, a 5-hydroxytryptamine 1B/1D receptor agonist, promotes myelination in culture. Zolmitriptan up-regulated myelin-related genes in primary Schwann cells and increased proliferating Schwann cells along axons in DRG explant cultures of Tr-Ncnp mice. Furthermore, we observed that chronic administration of zolmitriptan ameliorates sensorimotor dysfunction in Tr-Ncnp mice. Collectively, these results suggest that 5-HT1B/1D receptor agonists may increase Schwann cells participating in myelination, and consequently ameliorate myelination impairment in peripheral neuropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Peripheral Nervous System Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.
ORCID-Profile: Toshiyuki Araki
Förderung
- Japan Society for the Promotion of Science
- Dainippon Sumitomo Pharma
- Masato Kawano Memorial Public Interest Foundation for Promotion of Pediatrics
- National Center of Neurology and Psychiatry
Zitieren
APA
Kobayashi-Ujiie, Y., Hiraki-Kamon, K., Wakatsuki, S., & Araki, T. (2026). 5-HT1B receptor agonists promote Schwann cell myelination. PLOS One, 21(3), e0345946. https://doi.org/10.1371/journal.pone.0345946
Vancouver
Kobayashi-Ujiie Y, Hiraki-Kamon K, Wakatsuki S, Araki T. 5-HT1B receptor agonists promote Schwann cell myelination. PLOS One. 2026;21(3):e0345946. doi:10.1371/journal.pone.0345946
BibTeX
@article{KobayashiUjiie2026,
author = {Kobayashi-Ujiie, Yuka and Hiraki-Kamon, Keiko and Wakatsuki, Shuji and Araki, Toshiyuki},
title = {5-HT1B receptor agonists promote Schwann cell myelination},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0345946},
doi = {10.1371/journal.pone.0345946}
}
EUVIMED